SCHEDULE: Trails Edge Capital Discloses 9.9% Stake in Milestone Pharmaceuticals
Schedule 13G Filing
Trails Edge Capital Partners, LP, along with its affiliates, has reported a 9.9% beneficial ownership stake in Milestone Pharmaceuticals Inc., totaling 8,847,882 common shares.
Summary
- Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai collectively reported beneficial ownership of 8,847,882 common shares of Milestone Pharmaceuticals Inc.
- This aggregate amount represents 9.9% of the outstanding common shares of Milestone Pharmaceuticals Inc. as of July 14, 2025.
- The ownership includes 5,333,333 shares held directly by Trails Edge Biotechnology Master Fund, LP.
- Additionally, 3,514,549 shares are held through Series A warrants directly by Trails Edge Biotechnology Master Fund, LP.
- The calculation of beneficial ownership excludes 1,818,784 shares underlying Series A Warrants and 5,333,333 shares underlying Series B Warrants due to an issuance limitation.
- This limitation prohibits the holder from exercising warrants if it would result in beneficial ownership exceeding 9.99% of the outstanding shares.
- The ownership percentage is based on 84,964,273 shares reported as issued and outstanding in Milestone Pharmaceuticals Inc.'s Rule 44(b)(5) Prospectus Supplement filed on July 14, 2025.
- Trails Edge Capital Partners, LP acts as the investment manager to Trails Edge Biotechnology Master Fund, LP.
- Ortav Yehudai, as the Chief Investment Officer of Trails Edge Capital Partners, LP, exercises voting and investment discretion over these securities.
Sentiment
Score: 6
Explanation: The document is a factual disclosure of beneficial ownership, which is generally neutral. The acquisition of a significant stake (9.9%) by an investment firm could be viewed positively by the market as a vote of confidence, but the document itself does not contain explicit positive or negative sentiment.
Risks
- The beneficial ownership is subject to an issuance limitation on Series A and Series B warrants, preventing exercise if it would cause the holder's beneficial ownership to exceed 9.99% of the outstanding shares.
Future Outlook
The document is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or strategic direction.
Industry Context
This filing indicates a significant investment by Trails Edge Capital Partners, LP and its affiliates in Milestone Pharmaceuticals Inc., a company in the pharmaceutical sector. Such a substantial stake by an investment firm can signal confidence in the company's long-term prospects or a strategic investment play within the biotechnology industry.
Stakeholder Impact
- Shareholders: The disclosure of a significant 9.9% stake by an investment firm could be perceived as a positive signal, potentially influencing investor confidence and share price. It also indicates a large institutional holder with potential influence.
Key Dates
| Date | Description |
|---|---|
| 07/14/2025 | Date of event which requires filing of this statement; also the date Milestone Pharmaceuticals Inc.'s Rule 44(b)(5) Prospectus Supplement was filed, reporting 84,964,273 shares outstanding. |
| 07/21/2025 | Date the Schedule 13G statement was signed and filed. |
Keywords
Milestone Pharmaceuticals Inc., Trails Edge Capital Partners, Trails Edge Biotechnology Master Fund, Ortav Yehudai, Schedule 13G, Beneficial Ownership, Common Shares, Investment Management, Warrants, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.